Australian clinical stage cell therapy company Chimeric Therapeutics (ASX:CHM) has updated investors to confirm that all patients dosed in the first cohort in the phase one CLTX CAR-T cell clinical trial have now advanced beyond the 28-day follow up period without experiencing dose-limiting toxicities. …
Chimeric updates on CLTX CAR-T cell clinical trial
April 22, 2021 Latest NewsBioPharmaAustralian Biotech
Latest Video
New Stories
-
The symptoms have been identified, but the widely held belief about the cause is a miss
September 30, 2025 - - Latest News -
UK companies are granted more time to decide on pricing agreement
September 29, 2025 - - Latest News -
Anatara strengthens board with the appointment of Dirk van Dissel
September 29, 2025 - - Australian Biotech -
CLINUVEL advances next-generation peptide drug formulations
September 29, 2025 - -
Alterity Therapeutics targets major market with ATH434 in Multiple System Atrophy
September 29, 2025 - - Australian Biotech -
Lower than expected uptake of new therapies impacts PBS spend
September 29, 2025 - - Latest News -
Chimeric reports encouraging early data from CHM CDH17 trial
September 29, 2025 - - Australian Biotech